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Abbreviations 
GABAAR, GABA type-A receptor 
IPSC, inhibitory postsynaptic current 
DMEM-FBS, Dulbecco’s Modified Eagles Medium supplemented with 10 % fetal bovine serum 
 
Highlights 
• α5β1γ2, α5β2γ2 and α5β3γ2 GABAARs mediate robust IPSCs in heterosynapses 
• Their IPSC decay rates are slow and dominated by intrinsic channel closing rates 
• α5β1γ2L GABAARs are located postsynaptically whereas the others are perisynaptic 
• four α5-specific inhibitors caused distinct patterns of isoform-specific inhibition 
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Abstract 
α5-containing GABAARs are potential therapeutic targets for clinical conditions including 
age-related dementia, stroke, schizophrenia, Down syndrome, anaesthetic-induced amnesia, anxiety 
and pain. α5-containing GABAARs are expressed in layer 5 cortical neurons and hippocampal 
pyramidal neurons where they mediate both tonic currents and slow inhibitory postsynaptic currents 
(IPSCs). A range of drugs has been developed to specifically modulate these receptors. The main 
α5-containing GABAARs that are likely to exist in vivo are the α5β1γ2, α5β2γ2 and α5β3γ2 
isoforms. We currently have few clues as to how these isoforms are distributed between synaptic 
and extrasynaptic compartments or their relative roles in controlling neuronal excitability. 
Accordingly, the aim of this study was to define the basic biophysical and pharmacological 
properties of IPSCs mediated by the three isoforms in a hippocampal neuron-HEK293 cell co-
culture assay. The IPSC decay rates were slow (α5β1γ2L: 45 ms; α5β1γ2L: 80 ms; α5β3γ2L: 184 
ms) and were largely dominated by the intrinsic channel deactivation rates. By comparing IPSC rise 
times, we inferred that α5β1γ2L GABAARs are located postsynaptically whereas the other two are 
predominantly perisynaptic. α5β3γ2L GABAARs alone mediated tonic currents. We quantified the 
effects of four α5-specific inverse agonists (TB-21007, MRK-016, α5IA and L-655708) on IPSCs 
mediated by the three isoforms. All compounds selectively inhibited IPSC amplitudes and 
accelerated IPSC decay rates, albeit with distinct isoform specificities. MRK-016 also significantly 
accelerated IPSC rise times. These results provide a reference for future studies seeking to identify 
and characterize the properties of IPSCs mediated by α5-containing GABAAR isoforms in neurons. 
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α5IA: PubChem CID: 6918451 
L-655708: PubChem CID: 5311203 
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Introduction 
GABAA receptors (GABAARs) are ligand-gated Cl- channels that mediate synaptic and 
extrasynaptic inhibition in the brain. As GABAARs are pentameric oligomers constructed from a 
family of 19 different subunits (α1-6, β1-3, γ1-3, δ, ε, π, θ and ρ1-3), the number of possible 
stoichiometries is enormous. As with many other types of ion channel, their biophysical and 
pharmacological properties and their cellular and subcellular distribution patterns vary according to 
their subunit stoichiometry (D'Hulst et al., 2009; Mele et al., 2016; Sieghart and Sperk, 2002; 
Vithlani et al., 2011). α5-containing GABAARs are found mainly in layer 5 cortical neurons and 
hippocampal pyramidal neurons where they are located both extrasynaptically and synaptically 
(Caraiscos et al., 2004; Collinson et al., 2002; Sieghart, 1995; Sieghart and Sperk, 2002; Yamada et 
al., 2007). Because extrasynaptic α5-containing GABAARs can be activated by the low ambient 
GABA concentrations that exist outside of the synapse, they generate a persistent Cl- ‘leak’ current 
that tonically inhibits neurons (Farrant and Nusser, 2005; Lee and Maguire, 2014). Synaptic α5-
containing GABAARs contribute a slow component to the GABAergic inhibitory postsynaptic 
currents (IPSCs) (Caraiscos et al., 2004; Collinson et al., 2002; Glykys et al., 2008; Hausrat et al., 
2015; Prenosil et al., 2006; Vargas-Caballero et al., 2010; Zarnowska et al., 2009). α5-containing 
GABAARs are considered promising therapeutic targets for a range of clinical conditions including 
age-related dementia, stroke, schizophrenia, Down syndrome, anaesthetic-induced amnesia, anxiety 
and pain (Botta et al., 2015; Brickley and Mody, 2012; Clayton et al., 2015; Perez-Sanchez et al., 
2017; Rudolph and Mohler, 2014; Soh and Lynch, 2015), and indeed a wide range of drugs has 
been developed to specifically modulate them (Clayton et al., 2015; Soh and Lynch, 2015).  
The main α5-containing GABAARs that are likely to exist in vivo are the α5β1γ2, α5β2γ2 
and α5β3γ2 isoforms (Olsen and Sieghart, 2009). We currently have few clues as to how these 
isoforms are distributed between synaptic and extrasynaptic compartments or their relative 
contributions to controlling neuronal excitability. A first step towards addressing this would be to 
define the basic biophysical and pharmacological properties of IPSCs mediated by individual α5-
containing GABAAR isoforms. To date, the pharmacological profiles of α5-specific drugs have 
been evaluated under equilibrium conditions, whereby the drug and a low (e.g., EC20) concentration 
of GABA have been co-applied for an extended period (typically several seconds) (Ballard et al., 
2009; Chambers et al., 2002; Chambers et al., 2003; Quirk et al., 1996; Sternfeld et al., 2004). 
These conditions are relevant to quantifying drug effects on tonically-activated GABAARs. 
However, they are not relevant to IPSCs because the kinetics of the synaptic agonist transient plays 
a crucial role in determining the susceptibility of IPSCs to pharmacological modulation (Barberis et 
al., 2011). 
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The aim of this study was to characterize the physiological and pharmacological properties 
of IPSCs mediated by the α5β1γ2L, α5β2γ2L and α5β3γ2L GABAARs to improve our 
understanding of their individual roles in controlling neuronal excitability and the mechanisms by 
which α5-modulating drugs influence neuronal activity. When taken in conjunction with human 
clinical, animal behavioural and cell biological studies, this information should help provide new 
insights into which isoform should be preferentially targeted (and how it should be targeted) when 
seeking to treat the various disorders for which α5-containing GABAAR modulation has been 
implicated.  
The study of individual GABAAR isoforms in neurons is confounded by the large number of 
GABAAR isoforms present and the unknown or poor selectivity profiles of available 
pharmacological blockers. This problem can be circumvented via the use of a neuron-HEK293 cell 
co-culture system, whereby functional ‘heterosynapses’ can be induced to form between neuronal 
presynaptic terminals and HEK293 cells that recombinantly express the GABAAR isoform of 
interest (Brown et al., 2014; Dixon et al., 2015; Dong et al., 2007). Using such a system, we 
investigated the biophysical properties of IPSCs mediated by recombinant α5β1γ2L, α5β2γ2L and 
α5β3γ2L GABAARs and characterized their sensitivity to four widely-used α5-specific inverse 
agonists: TB-21007, MRK-016, α5IA and L-655708. 
 
Methods 
Drugs  
TB-21007 and MRK-016 were obtained from Tocris Bioscience. Bicuculline methiodide, 
α5IA, L-655708, 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), AP5, tetrodotoxin (TTX) and 
GABA were obtained from Sigma-Aldrich. TB-21007, MRK-016, bicuculline methiodide, α5IA 
and L-655708 were dissolved in DMSO as 10 mM stock solutions. CNQX and AP5 stocks were 
dissolved in DMSO at 1 mM and 20 mM, respectively. The TTX and GABA stocks were dissolved 
in H2O at 1 and 500 mM, respectively. All stocks were stored at -20 oC until use.   
 
Primary culture of cortical neurons and hippocampal neurons  
Cortical neurons and hippocampal neurons were prepared using methods as recently 
described (Dixon et al., 2015). Briefly, E18 timed-pregnant rats were euthanized via CO2 inhalation 
in accordance with procedures approved by the University of Queensland Animal Ethics 
Committee. The cortices and hippocampi were rapidly removed, triturated and plated onto poly-D-
lysine-coated coverslips in a 4-well plate at a density of 8-10 x 104 cells/well, and cultured for 3-4 
wk until spontaneous IPSCs could be detected. The cells were initially cultured in Dulbecco’s 
Modified Eagles Medium supplemented with 10 % fetal bovine serum (DMEM-FBS). After 24 h 
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the entire DMEM-FBS medium was replaced with Neurobasal medium including 2 % B27 and 1 % 
GlutaMAX supplements. A second (and final) feed 1 wk later replaced half of this medium with 
fresh Neurobasal medium. Neurons were used in co-culture experiments between 3-5 wk later. 
 
HEK 293 cell culture, transfection and heterosynapse formation 
HEK293 cells were cultured in DMEM-FBS until approximately 90% confluent. One day 
prior to transfection, they were trypsinized and plated onto glass coverslips in 35 mm culture dishes 
at a density of 5 x 103 cells/dish.  
This study employed the following plasmid DNAs: human GABAAR α5 (pcDNA3.1Zeo), 
human GABAAR β1 (pcDNA3.1Zeo), human GABAAR β2 (pcDNA3.1Zeo), human GABAAR β3 
(pcDNA Zeo), human GABAAR γ2L (pcDNA3.1), mouse neuroligin 2A (pNice) and GFP 
(pEGFP). GABAAR clones were obtained from Prof. Neil Harrison (Columbia University), whereas 
neuroligin 2A was obtained from Addgene (plasmid 15259) and pEGFP from Clontech. Each 35 
mm dish of HEK293 cells was transfected with GFP, α5, β and γ2L GABAAR plasmid DNAs in a 
ratio of 1:1:1:5. Neuroligin 2A (100 ng) was also transfected, with the total plasmid DNA amount 
totalling around 0.5 µg per dish. Transfection was performed via a Ca2+ phosphate-DNA co-
precipitation method for 5-20 h in a 3% CO2 incubator and terminated by washing cells twice with 
divalent cation-free phosphate buffered saline. Cells were trypsinized the next day, centrifuged and 
re-suspended in Neurobasal medium (including 2% B27 and 1% GlutaMAX supplements) then 
seeded onto the neurons. One 35 mm dish of HEK293 cells was typically sufficient to seed four 
coverslips of neurons. Once seeded with HEK293 cells, the co-cultures were returned to the 
incubator overnight to allow synapses to form. Cultures were used for patch clamp recording over 
the following 2-3 days. 
 
Electrophysiology 
Patch clamp recordings were performed at room temperature (22 ± 1°C) at a clamped 
potential of −70 mV, in whole-cell or outside-out configurations. All recordings were performed 
using a Multiclamp 700B amplifier and pClamp10 software (Molecular Devices), filtered at 4 kHz 
and sampled at 10 kHz. Patch pipettes (4 – 8 MΩ resistance) were fabricated from borosilicate glass 
(GC150F-7.5, Harvard Apparatus) and filled with an internal solution comprising (in mM): 145 
CsCl, 2 CaCl2, 2 MgCl2, 10 HEPES and 10 EGTA, adjusted to pH 7.4 with CsOH. The extracellular 
solution comprised (in mM) 140 NaCl, 5 KCl, 2 CaCl2, 1 MgCl2, 10 HEPES and 10 D-glucose, 
adjusted to pH 7.4 with NaOH.  
  For macropatch recordings, pipettes were fire-polished to a resistance of ~10 MΩ and filled 
with the same internal solution. Outside-out patches pulled from transfected HEK293 cells were 
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activated by brief (<1 ms) exposure to agonists using a piezo-electric translator (Siskiyou). The 
speed of the solution exchange system was regularly calibrated by rapidly switching the solution 
perfusing an open patch pipette between standard extracellular solution and an extracellular solution 
that had been diluted by 50% with distilled water. By monitoring the resulting pipette current, we 
were able to ensure that the solution perfusing the macropatch was completely exchanged within 
200 µs (Dixon et al., 2014).  
 
Data analysis  
Analyses of IPSC amplitude, 10−90% rise time, and decay time constant were performed 
using Axograph X (Axograph Scientific). Only cells with a stable series resistance of <25 MΩ 
throughout the recording period were selected for analysis. IPSCs were detected using a 
semiautomated sliding template. Each detected event was visually inspected and only those with no 
inflections in the rising or decay phases were included. All selected events from a single cell were 
digitally averaged. Parameters derived from these digitally averaged waveforms were then pooled 
with those form other cells to obtain group data. 
To calculate macroscopic current decay time constants, digitally averaged macroscopic 
recordings were fitted with double-exponential functions in Axograph X, and a weighted time 
constant was calculated from individual time constants (τ1, τ2) and their relative amplitude (A1, 
A2) as follows: τweighted = (τ1×A1+τ2×A2)/(A1+A2).  
Displayed averaged data represent group means ± SEMs. The Hill equation was used to 
calculate the saturating current magnitude (Imax), half-maximal concentration (EC50) and Hill 
coefficient (nH) values for GABA activation. Individual concentration-response relationships were 
fitted using a nonlinear least squares algorithm (SigmaPlot 11.0; Jandel Scientific, San Rafael, CA, 
USA). Statistical analysis and graphing were performed with SigmaPlot 11.0. Group data were 
tested for normal probability distribution and for significant differences between groups using one-
way ANOVA. Pair-wise comparisons were determined using Tukey’s test, where P ≤ 0.05 was 
taken as the significance threshold.  
 
Results  
 
GABA concentration-response relationships for α5β1γ2L, α5β2γ2L and α5β3γ2L GABAARs 
Previously published GABA EC50 values for α5-containing GABAARs expressed in 
HEK293 cells vary widely. For example, reported EC50 values for α5β3γ2 GABAARs range from 
1.4 µM (Mortensen et al., 2011), to 10.8 µM (Burkat et al., 2014) and 19.4 µM (Caraiscos et al., 
2004). Similarly, EC50 values for α5β2γ2 GABAARs range from 0.8 µM (Kumar and Dillon, 2016) 
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to 10.2 µM (Petroski et al., 2006). GABA EC50 values for the three isoforms expressed in HEK293 
cells have never been compared in a single study, although a single study performed on Xenopus 
oocyte-expressed receptors reported remarkably consistent EC50 values (31 – 41 µM) for the three 
isoforms (Karim et al., 2013). We quantified the GABA concentration-response relationships for 
α5β1γ2L, α5β2γ2L and α5β3γ2L GABAARs expressed in HEK293 cells. Sample currents recorded 
in response to increasing GABA concentrations for each isoform are shown in Fig. 1A. The mean 
concentration-response relationships are shown in Fig. 1B with mean parameters of best fit to the 
Hill equation summarized in Table 1. The threshold concentrations for GABA activation were in 
the 1-3 µM range and EC50 values were reasonably consistent among the isoforms, ranging between 
9.6 and 15.4 µM.  
 
Properties of IPSCs mediated by α5β1γ2L, α5β2γ2L and α5β3γ2L GABAARs  
Whole cell recordings from transfected HEK293 cells in co-culture with cortical neurons 
exhibited robust, spontaneous IPSCs with amplitudes up to 1000 pA for each of the three isoforms 
(Fig. 2A). Fig. 2B shows digitally averaged and normalized IPSCs from single HEK293 cells 
expressing each isoform. Mean IPSC 10-90 % rise times, decay time constants and amplitudes, 
measured from 14 or 15 digitally averaged IPSCs, are presented in Figs. 2C-E. 
IPSCs mediated by α5β1γ2L GABAARs activated rapidly with a mean 10-90 % rise time of 
0.96 ± 0.07 ms and decayed rapidly with a mean decay time constant of 45 ± 3 ms (both n = 15 
cells). IPSCs mediated by α5β2γ2L GABAARs activated and decayed significantly more slowly, 
with a mean 10–90% rise time of 3.5 ± 0.2 ms and a mean decay time constant of 80 ± 4 ms (both p 
< 0.01 by two-way ANOVA, n = 14 cells). The α5β3γ2L GABAARs mediated IPSCs with much 
longer decay time constants (184 ± 14 ms, p < 0.01, n =15 cells) than either the α5β1γ2L or 
α5β2γ2L isoforms (Fig. 2D). This isoform also exhibited slow IPSC rise times (Fig. 2C). Thus, the 
β subunit has a strong influence on the rise and decay kinetics of IPSCs mediated by α5-containing 
GABAARs.  
 
Identification of the isoform responsible for tonic GABA currents in heterosynapses  
Tonic chloride flux in hippocampal neurons is thought to be mediated exclusively by 
α5β3γ2 GABAARs (Zarnowska et al., 2009). We thought to verify this in heterosynapses by 
assessing the relative contributions of the three α5-containing isoforms to the net leak current. 
Using 100 µM bicuculline to block both GABAergic IPSCs and tonic currents, we found the mean 
tonic current magnitude in synaptically-connected HEK293 cells expressing α5β3γ2L GABAARs to 
be 93 ± 20 pA (n = 8 cells) (Fig. 3A, E). In contrast, 100 µM bicuculline had no effect on the 
baseline current in more than 30 synaptically-connected HEK293 cells expressing α5β1γ2L or 
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α5β2γ2L GABAARs (Fig. 2B, C, E). By comparison, we found the mean bicuculline-sensitive tonic 
current magnitude in cultured rat hippocampal neurons to be 102 ± 15 pA (n = 8 cells) (Fig. 2D, E). 
From these data we infer that the tonic extrasynaptic GABA current in our heterosynaptic system is 
mediated primarily by α5β3γ2L GABAARs.  
To determine whether this current was due to spontaneous channel activity (Wlodarczyk et 
al., 2013) or to activation by ambient GABA released from local neurons or glia (Attwell et al., 
1993; Lee et al., 2010; Semyanov et al., 2004), we applied 100 µM bicuculline to isolated (i.e., not 
co-cultured) HEK293 cells expressing α5β3γ2L GABAARs. In each of 7 cells, we found that 100 
µM bicuculline had no detectable effect on the baseline current level (not shown), implying that the 
bicuculline-sensitive tonic current in our heterosynaptic preparation is mediated by ambient GABA. 
 
Macropatch currents mediated by α5β1γ2L, α5β2γ2L and α5β3γ2L GABAARs  
To determine whether the β subunit-dependent variation in IPSC kinetics was due to 
variations in the intrinsic receptor gating properties or to differential interactions with synapse-
specific molecules (Barberis et al., 2011; Dixon et al., 2017), we recorded ensemble currents from 
outside-out patches excised from HEK293 cells that expressed either α5β1γ2L, α5β2γ2L or 
α5β3γ2L GABAARs. To mimic synaptic activation conditions, we applied a saturating (5 mM) 
GABA concentration for 1 ms via a piezoelectric translation device.  Two standard exponentials 
functions were required to fit the deactivation phase of macropatch currents for the three receptor 
subtypes. The individual time constants (and areas) are tabulated in Table 2. Examples of ensemble 
currents activated under these conditions for the three receptor isoforms are shown in Fig. 4A with 
mean weighted deactivation time constants and 10-90 % rise times summarized in Fig. 4B and C. A 
two-way ANOVA revealed no statistically significant differences in rise times among receptor 
isoforms (Fig. 4C). However, the mean deactivation time constant for α5β2γ2L GABAARs (56 ± 7 
ms, n =11 patches) was significantly slower than for α5β1γ2L GABAARs (23 ± 6 ms, n = 7 patches; 
p < 0.01). The presence of the β3 subunit slowed the current deactivation time constant further to 
160 ± 13 ms (n = 6; p < 0.05 relative to α5β1γ2L and α5β2γ2L GABAARs). A one-way ANOVA 
revealed a highly significant correlation between the β subunit and the ensemble current decay of 
α5-containing GABAARs (p ≤ 0.001).  
Fig. 4D demonstrates that the macropatch current decay time constants correlated 
reasonably well with the IPSC decay time constants, although in each case the macropatch currents 
decayed significantly faster. In contrast, the macropatch current rise times were dramatically faster 
than the IPSC rise times for all three isoforms (Fig. 4E). Possible explanations for these results are 
provided below. 
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Effects of TB-21007, MRK-016, α5IA and L-655708 on IPSCs mediated by α5β1γ2L, α5β2γ2L and 
α5β3γ2L GABAARs 
A structurally diverse range of drugs specific for α5-containing GABAARs has been 
developed (Clayton et al., 2015; Soh and Lynch, 2015). These drugs have generally been tested on 
only a single α5-containing isoform, most commonly α5β3γ2, under equilibrium conditions in the 
presence of a low (typically EC20) GABA concentration (Ballard et al., 2009; Chambers et al., 
2002; Chambers et al., 2003; Quirk et al., 1996; Sternfeld et al., 2004). These conditions are 
relevant to evaluating drug effects on tonically-activated receptors. However, synaptically- and 
tonically-activated GABAARs may have very different pharmacological properties because the 
potency of ion channel modulators is dominated by two factors, agonist concentration and channel 
open time, which vary drastically between synaptic- and extrasynaptically-expressed receptors 
(Barberis et al., 2011). An investigation of the efficacy of α5-specific modulators on IPSCs 
mediated by the major α5-containing isoforms is thus warranted. Here we compared the effects of 
saturating (1 µM) concentrations of four α5-GABAAR-specific inverse agonists, TB-21007, MRK-
016, α5IA and L-655708, on IPSCs mediated by α5β1γ2L, α5β2γ2L and α5β3γ2L GABAARs. The 
results are presented in Figs. 5 and 6 with all results summarized in Table 3. 
Examples of the effect of TB-21007 on IPSCs mediated by the three isoforms are shown in 
Fig. 5A-C. Digitally-averaged, normalised IPSCs from the corresponding cells are shown to the 
right of each panel. The mean effects of TB-21007 on mean IPSC 10-90 % rise times, decay time 
constants and amplitudes are presented in Fig. 5D-F. TB-21007 had no effect on the activation rate 
of IPSCs mediated by any isoform. Similarly, TB-21007 did not affect α5β1γ2L- and α5β2γ2L-
mediated IPSC decay time constants although it significantly slowed the decay time constant of 
IPSCs mediated by α5β3γ2L GABAARs. The amplitude of IPSCs mediated by α5β2γ2L and 
α5β3γ2L GABAARs were also significantly reduced, whereas those mediated by α5β1γ2L 
GABAARs were not affected.  These results indicate that TB-21007 exerts a differential effect on 
the major α5-containing isoforms. 
MRK-016 significantly decreased the 10-90 % activation times of IPSC mediated by all 
three isoforms (Fig. 6A). It also significantly reduced the amplitude of α5β1γ2L and α5β2γ2L-
mediated IPSCs and significantly reduced the decay time constant for α5β3γ2L-expressing 
GABAARs to 73 ± 2% of control (Fig. 6A).   
As for TB-21007, α5IA had no effect on the activation rate of any isoform (Fig. 6B). 
However, it significantly inhibited the peak magnitude of IPSCs mediated by α5β1γ2L and 
α5β2γ2L GABAARs but not of α5β3γ2L GABAARs. α5IA also significantly shortened the decay 
time constant of IPSCs mediated by α5β2γ2L GABAARs and α5β3γ2L GABAARs but not of 
α5β1γ2L GABAARs (Fig. 6B).  
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L-655708 exerted relatively weak effects on IPSCs (Fig. 6C). It significantly reduced the 
peak IPSC magnitude of α5β2γ2L GABAARs and the decay time constant of IPSCs mediated by 
α5β3γ2L GABAARs. 
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Discussion 
 
Comparison of the physiological properties of the three isoforms 
The unique advantage of heterosynapses is that they permit the investigation of the 
physiological and pharmacological properties of IPSCs mediated by defined GABAAR isoforms. 
However, as HEK293 cells do not express all necessary postsynaptic clustering proteins at 
appropriate levels for synaptogenesis, it is possible that the synaptic cleft geometry and the 
GABAAR receptor clustering mechanisms in our heterosynapses may not be identical to those of 
native neuronal synapses. This could result in aberrant neurotransmitter concentration profiles that 
could affect IPSC kinetics. This uncertainty is the main limitation of the technique. Moreover, 
cytoplasmic proteins such as radixin or AP2 clathrin adaptor protein that trap α5β3γ2L GABAARs 
in extrasynaptic compartments (Hausrat et al., 2015; Vien et al., 2015) may not be functional in 
HEK293 cells. Irrespective of these potential limitations, a range of recombinant GABAAR 
isoforms has been found to mediate heterosynaptic IPSCs with kinetics similar to those mediated by 
the same isoforms in neurons (Dixon et al., 2014; Dixon et al., 2015; Dixon et al., 2017; Fuchs et 
al., 2013; Wu et al., 2012). Because the kinetics of IPSCs mediated by defined α5-containing 
GABAARs in vivo are not known, this comparison is not possible. However, α5-containing 
GABAARs in neuronal synapses mediate a slowly-decaying IPSC component consistent with our 
results (Caraiscos et al., 2004; Collinson et al., 2002; Glykys et al., 2008; Hausrat et al., 2015; 
Prenosil et al., 2006; Vargas-Caballero et al., 2010; Zarnowska et al., 2009). 
  Fast IPSC rise times imply expression within the postsynaptic density whereas slow rise 
times suggest perisynaptic expression (Farrant and Nusser, 2005; Wu et al., 2012). Of the receptors 
investigated here, the α5β1γ2L GABAAR exhibited the fastest rise times (~1 ms). Notably, the 
major synaptically-expressed α1β2γ2 isoform also exhibits a rise time of ~1 ms irrespective of 
whether it is expressed in heterosynapses (Dixon et al., 2014) or neurons (Eyre et al., 2012; Okada 
et al., 2000). From this we infer that α5β1γ2L GABAARs are also located in postsynaptic densities 
of heterosynapses close to transmitter release sites. 
In contrast, the α5β2γ2L and α5β3γ2L isoforms exhibited IPSC rise times of ~3 ms. As both 
receptors were activated rapidly upon GABA application (rise times < 0.4 ms, Fig. 4C), the slow 
IPSC rise times were most likely dominated by the neurotransmitter access time. In a previous 
heterosynapse study, IPSC rise times of 3-5 ms were shown to be associated with perisynaptic 
GABAARs (Wu et al., 2012).  We thus infer that the α5β2γ2L and α5β3γ2L GABAARs have a 
reduced propensity to cluster at postsynaptic densities, and may thus be predominantly located in 
the perisynaptic region.  
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The decay time constants for all three isoforms correlated well with the intrinsic channel 
closing rates as determined by fast GABA application (Fig. 4C). This fits well with our recent 
Monte Carlo simulations that demonstrated GABAergic IPSC decay time constants are not affected 
by changes in a variety of synapse parameters, including GABA diffusion coefficient, synaptic cleft 
width, postsynaptic density size or GABAAR clustering density (Dixon et al., 2017). 
Extrasynaptic GABAergic leak currents can be mediated either by a low concentration of 
extrasynaptic GABA activating high affinity, non-desensitizing receptors (Lee and Maguire, 2014) 
or by spontaneously-activating receptors in the absence of GABA (Wlodarczyk et al., 2013). In our 
heterosynapse preparation, we found that tonic inhibition was it mediated only by α5β3γ2L 
GABAARs (Fig. 3). As α5β3γ2L GABAARs exhibited no spontaneous activity when expressed in 
HEK293 cells in the absence of neurons and glia, we infer that the extrasynaptic α5β3γ2L 
GABAARs in heterosyaptic preparation are activated by GABA released from local neurons or glia. 
Although all three α5-containing receptors exhibited comparable sensitivities to low (3 µM) 
concentrations of GABA (Fig. 1), only the α5β3γ2L isoform was tonically active, suggesting it is 
located in the appropriate extrasynaptic locations so as to sense extrasynaptically-released GABA.  
Putting these observations together, we infer that α5β1γ2L GABAARs are located mainly 
within postsynaptic densities, α5β2γ2L GABAARs tend to be located perisynaptically and α5β3γ2L 
GABAARs tend to be located both perisynaptically and in extrasynaptic regions close to tonic 
GABA release sites. Of course, it remains to be determined whether these locations also pertain to 
neurons. Finally, the decay time constants of the three isoforms varied over a wide range (i.e., 
α5β1γ2L: 45 ms; α5β1γ2L: 80 ms; α5β3γ2L: 184 ms) and we infer that these were largely 
dominated by the respective intrinsic channel closing rates and not their synaptic versus 
perisynaptic locations. 
 
Pharmacological properties of the three isoforms 
TB-21007 (sometimes referred to as compound 43) was first reported in 2003 as a selective 
inverse agonist of α5β3γ2 GABAARs and was shown to inhibit the steady-state current with an 
efficacy of -51 % and a Ki of 1.6 nM (Chambers et al., 2003).  When delivered intraperitoneally to 
rats, TB-21007 enhanced cognitive performance without the anxiogenic or pro-convulsive effects 
usually associated with non-specific GABAAR inverse agonists (Chambers et al., 2003). Here we 
showed that a saturating (1 µM) concentration of TB-21007 preferentially inhibited IPSCs mediated 
by α5β3γ2L GABAARs with an efficacy of -38 %. It exhibited a weaker inhibitory effect on IPSCs 
mediated by α5β2γ2L GABAARs and did not affect those mediated by α5β1γ2L GABAARs at all. 
Of the compounds tested here, TB-21007 exhibited the highest selectivity for α5β3γ2L GABAARs 
over other α5-containing isoforms.  
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MRK-016 was first described in 2009 where it was shown to selectively inhibit steady-state 
currents mediated by α5β3γ2 GABAARs with an efficacy of -55 % and a Ki of 1.4 nM  (Atack et al., 
2009). Similar to TB-21007, it enhanced cognitive performance in rats without evoking anxiogenic 
or convulsive side-effects. It has also been shown to exhibit anti-depressant activity in rats (Fischell 
et al., 2015). However, MRK-016 was poorly tolerated in elderly humans which precluded further 
clinical development (Atack et al., 2009). We found that although MRK-016 selectively reduced the 
IPSC decay time constant in α5β3γ2L GABAARs, it also reduced the magnitude of IPSCs mediated 
by α5β1γ2L and α5β2γ2L GABAARs. It thus appears to have minimal utility for distinguishing 
among α5-containing isoforms.  
α5IA was first described in 2009 where it selectively inhibited steady-state currents 
mediated by α5β3γ2 GABAARs with an efficacy of -29 % and a Ki of 1.4 nM  (Dawson et al., 
2006). It exhibited cognitive enhancing properties in rodents but not in elderly humans (Atack, 
2010). We found that a saturating concentration of α5IA modestly but significantly reduced the 
decay time constant of IPSCs mediated by α5β2γ2L and α5β3γ2L GABAARs and reduced the 
magnitude of IPSCs mediated by α5β1γ2L and α5β2γ2L GABAARs. Thus, similar to MRK-016, it 
appears to have minimal utility for discriminating among α5-containing isoforms.   
L-655708 was first reported as an α5-specific ligand  in 1996 (Quirk et al., 1996). It was 
subsequently shown to selectively inhibit steady-state currents mediated by α5β3γ2 GABAARs with 
an efficacy of -17 % and a Ki of 1.0 nM (Atack et al., 2006). In contrast to the three drugs described 
above, it achieves its selectivity via a higher binding affinity rather than by a greater inhibitory 
efficacy. Although it produced cognitive enhancement in rats, it was also anxiogenic, presumably 
due to off target effects on α2- and α3-containing isoforms (Atack et al., 2006). It presumably works 
most effectively on tonic currents in vivo as it exerted only minor effects on IPSCs mediated by α5-
containing isoforms investigated here.    
These results indicate that, with the possible exception of TB-21007, these drugs have weak 
and non-selective effects on IPSCs mediated by the major α5-containing GABAAR isoforms. These 
results suggest they cannot be used reliably as probes to pharmacologically define α5-mediated 
IPSC components in neurons.  
 
Conclusions 
The IPSC decay time constants of the three isoforms varied over a wide range (45 - 184 ms) 
and were largely dominated by the respective intrinsic channel deactivation rates. As IPSC duration 
is an important determinant of neuronal network functions including signal integration, oscillations 
and output firing rates, our results suggest that IPSCs mediated by the three major α5-containing 
isoforms may exert dramatically different effects on network activity. We also quantified the effects 
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of four α5-specific inverse agonists on IPSCs mediated by the three isoforms. Each of the four 
compounds inhibited IPSC amplitudes and durations, although with unique isoform-specific 
efficacies. MRK-016 also significantly accelerated IPSC rise times. The results may help provide a 
basis for understanding how the drugs are likely to differentially affect network activity. By 
comparing IPSC rise times, we infer that α5β1γ2L GABAARs are mainly located in the postsynaptic 
density whereas the other two isoforms are predominantly perisynaptic. We also present evidence 
that the α5β3γ2L GABAAR is tonically active, whereas α5β1γ2L and α5β2γ2L GABAARs are not. 
The physiological and pharmacological characterisation we present here provides a reference for 
future studies seeking to identify and characterize the synaptic properties of α5-containing 
GABAAR isoforms in neurons. 
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Figure Legends 
 
Figure 1. GABA sensitivity of α5-containing GABAARs. In this and all subsequent figures, data 
corresponding to α5β1γ2L, α5β2γ2L and α5β3γ2L receptors are colored green, orange and blue, 
respectively. (A) Examples of currents recorded in response to indicated GABA concentrations in 
HEK293 cells expressing each isoform. (B) Averaged GABA concentration-response relationships 
for the three isoforms. Mean parameters of best fit to the Hill equation are summarized in Table 1. 
 
Figure 2. Properties of spontaneous IPSCs recorded from heterosynapses incorporating α5β1γ2L, 
α5β2γ2L and α5β3γ2L GABAARs. (A) Representative recordings of IPSCs from HEK293 cells 
expressing each isoform. Grey traces are magnified from indicated sections of colored traces to 
show individual events. (B) Averaged (from 20-100 events), normalized IPSCs from individual 
cells expressing each isoform. (C) Mean 10-90 % rise times from cells expressing the indicated 
isoform. (D) Mean IPSC decay time constants from cells expressing the indicated isoform. (E) 
Mean IPSC amplitudes from cells expressing the indicated isoform. All n values are provided in the 
text.  Group means were tested for significance using one-way ANOVA and pair-wise comparisons 
were determined using Tukey’s test, where * p ≤ 0.05 and ** p ≤ 0.01 relative to each other 
isoform. 
 
Figure 3. Quantification of tonic GABAergic currents from heterosynaptically connected HEK293 
cells and from cultured rat hippocampal neurons. In all panels the purple bar indicates the duration 
of application of 100 µM bicuculline, a non-specific GABAAR blocker. (A-C) Sample recordings 
from cells incorporating α5β1γ2L, α5β2γ2L or α5β3γ2L GABAARs as indicated. Only α5β3γ2L 
GABAARs supported tonic currents. (D) A sample recording of phasic and tonic GABAergic 
currents from a cultured rat hippocampal neuron in the presence of TTX (200 nM), CNQX (10 µM) 
and AP5 (50 µM). (E) Mean amplitudes of tonic currents averaged from at least 8 cells expressing 
each recombinant GABAAR isoform and from hippocampal neurons. 
 
Figure 4. Outside-out macropatch recordings of currents mediated by each of the three α5-
containing GABAAR isoforms. (A) Sample recordings from macropatches expressing the indicated 
isoforms in response to ≤ 1 ms applications of saturating (5 mM) GABA. (B) Group averages of 
macropatch current deactivation time constants reveal a significant difference between the three 
isoforms. The time constants have been weighted. The individual time constants and their relative 
magnitudes are summarized in Table 2. (C) Group averages of 10-90 % activation times reveal no 
significant difference between isoforms. (D) Comparison of decay time constants for macropatch 
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and IPSC recordings, showing that the macropatch current decay rates are significantly faster than 
the corresponding IPSC decay rates. (E) Comparison of 10-90 % activation times for macropatch 
and IPSC recordings, showing that the macropatch current rise times are much faster than IPSC rise 
times. Mean results were averaged from 7 macropatches (α5β1γ2L), 11 macropatches (α5β2γ2L) 
and 6 macropatches (α5β3γ2L). *p < 0.05, **p < 0.01, ***p < 0.001. 
 
Figure 5. Effect of 1 µM TB-21007 on IPSCs recorded from heterosynaptically connected HEK293 
expressing α5β1γ2L, α5β2γ2L and α5β3γ2L GABAARs. (A) A sample recording of IPSCs from a 
cell expressing α5β1γ2L GABAARs in the absence (left) and presence (right) of TB-21007. In all 
panels, grey traces are magnified from indicated sections of colored traces to show individual 
IPSCs. Digitally averaged and normalized IPSCs from the displayed cell (inset right) suggest that 
TB-21007 did not affect the IPSC decay rate. (B) A similar recording of IPSCs from a cell 
expressing α5β2γ2L GABAARs suggest that TB-21007 decreased the amplitude but not the decay 
time constant of α5β2γ2L-mediated IPSCs. (C) A similar recording of IPSCs from a cell expressing 
α5β3γ2L GABAARs suggest that TB-21007 decreased the amplitude and decay time constant of 
α5β3γ2L-mediated IPSCs. (D) TB-21007 had no significant effect on IPSC rise times. (E) TB-
21007 significantly reduced the decay time constant of IPSCs mediated by α5β2γ2L and α5β3γ2L 
GABAARs. (F) TB-21007 significantly reduced the peak amplitude of IPSCs mediated by α5β2γ2L 
and α5β3γ2L GABAARs. The n values for all experiments are presented in Table 3.  Group means 
were tested for significance using one-way ANOVA and pair-wise comparisons were determined 
using Tukey’s test, where *p ≤ 0.05 and **p ≤ 0.01 relative to the pre-drug control. 
  
Figure 6. Effects of MRK-016, α5IA and L-655708 on the amplitudes, rise times and decay time 
constants of IPSCs mediated by α5β1γ2L, α5β2γ2L and α5β3γ2L GABAARs. The n values for all 
experiments are presented in Table 3. (A) Averaged effects of saturating (1 µM) MRK-016 reveal a 
significant reduction in IPSC rise times for all three isoforms, a significant acceleration in IPSC 
decay time constant for α5β3γ2L GABAARs and a significant reduction in magnitude of IPSCs 
mediated by α5β1γ2L and α5β2γ2L GABAARs. (B) Averaged effects of saturating (1 µM) α5IA 
reveal no effect on IPSC rise times, but a significant acceleration in decay time constant for 
α5β2γ2L and α5β3γ2L GABAARs and a significant reduction in magnitude of IPSCs mediated by 
α5β1γ2L and α5β2γ2L GABAARs. (C) Averaged effects of saturating (1 µM) L-655708 reveal no 
effect on IPSC rise times, but a significant acceleration in decay time constant for α5β3γ2L 
GABAARs and a significant reduction in magnitude of IPSCs mediated by α5β2γ2L GABAARs. 
Group means were tested for significance using one-way ANOVA and pair-wise comparisons were 
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determined using Tukey’s test, where *p ≤ 0.05 and **p ≤ 0.01 relative to the pre-drug control 
values. 
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Table 1. GABA activation properties of α5-containing isoforms. 
 
Isoform EC50 (µM) nH Imax (pA) n 
α5β1γ2L 13.2 ± 2.6 2.0 ± 0.4 3209 ± 638 4 
α5β2γ2L 15.4 ± 0.5 3.2 ± 0.2 1704 ± 265 4 
α5β3γ2L 9.6 ± 2.4 2.0 ± 0.4 3890 ± 553 5 
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Table 2. Individual time constants and relative areas for macropatch currents. 
 
Isoform τ1 (ms) A1 (%) τ2 (ms) A2 (%) τweighted (ms) n 
α5β1γ2L 108 ± 9 21 ± 1* 11.0 ± 0.8 73 ± 2* 23 ± 6 6 
α5β2γ2L 78 ± 2 57 ± 3 11.1 ± 0.8 31 ± 4 56 ± 7 11 
α5β3γ2L 285 ± 27*** 53 ± 1 20.4 ± 0.8 47 ± 2 160 ± 13 7 
 
Data represent mean ± SEM. *p < 0.05 **p ≤ 0.05 and ***p ≤ 0.001 relative to both non-asterisked 
values.  
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Table 3. Effects of 1 µM TB-21007, MRK-016, α5IA and L-655708IPSC on IPSC parameters 
expressed as a percentage of pre-drug control values.  
 
Drug  Isoform Rise time  
(% of control) 
Decay time constant 
(% of control) 
Amplitude 
(% of control) 
TB-21007 α5β1γ2L 111 ± 2   n=13 92 ± 2      n=12 124 ± 5      n=13 
 α5β2γ2L 106 ± 2   n=15 95 ± 1      n=14 78 ± 1*      n=11 
 α5β3γ2L 103 ± 1   n=11 81 ± 1*    n=10 62 ± 3**    n=8 
  
MRK-016 α5β1γ2L 90 ± 2*    n=7 97 ± 3        n=7 68 ± 1**    n=6 
 α5β2γ2L 81 ± 3*    n=7 91 ± 4        n=7 71 ± 4%*   n=7 
 α5β3γ2L 80 ± 3*    n=6 73 ± 2**    n=6 99 ± 5%     n=7 
  
α5IA α5β1γ2L 108 ± 2   n=12 110 ± 2      n=13 63 ± 3**    n=10 
 α5β2γ2L 96 ± 3     n=8 76 ± 2*      n=7  82 ± 2*      n=7 
 α5β3γ2L 97 ± 3     n=8 77 ± 2**    n=8 103 ± 4      n=9 
  
L-655708 α5β1γ2L 103 ± 2   n=12 103 ± 2      n=12 118 ± 4      n=12 
 α5β2γ2L 100 ± 2   n=13 116 ± 3      n=13 82 ± 2*      n=10 
 α5β3γ2L 111 ± 2   n=11 89 ± 2*      n=10 102 ± 4      n=11 
 
Group means were tested for significance using one-way ANOVA. Pair-wise comparisons were 
made relative to corresponding pre-drug control values and were determined using Tukey’s test, 
where *p ≤ 0.05 and *p ≤ 0.01 relative to corresponding pre-drug control. 
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Figure 1 
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Figure 2 
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